<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT2017091836266N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2017-10-28</date_registration>
      <primary_sponsor>Sabzevar University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation The Effect of Heparin Density unit 1000 with 5000 in Blood&#13;
 Sampling on the Results of Arterial Blood Gases in Intensive care unit in hospitals of sabzevar city in 1396.</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation The Effect of Heparin Density unit 1000 with 5000 in Blood&#13;
 Sampling on the Results of Arterial Blood Gases in Intensive care unit in hospitals of sabzevar city in 1396.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2017-10-27</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>152</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/27164</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Not randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Heparine Sodium.</hc_freetext>
      <i_freetext>Intervention 1: Equalize insulin syringes (manufactured by Iran Medical Company) with a 1000-heparin solution (for intervention group) for 1000 heparin units. One heparin injection of 5000 units of the Alborz Drug Company with four cc distilled water in one The 5-cc syringe of the Iran-Tehran Medical Product was diluted and delivered to the 5 th cc, of which every thirty thousand equals 1,000 units), at 0.1 Ml heparinized. Intervention 2: In the control group, based on the status quo, heparin ampoules of 5,000 units were found to be 0.1ml To insert the insulin syringes used for blood sampling, arterial blood gas was used.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Reza BORABADI</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Beheshti Relief Hospital, West Razi Street,  Sabzevar</address>
        <city>Sabzevar</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 51 4464 0115</telephone>
        <email>http://mail.medsab.ac.ir</email>
        <affiliation>Sabzevar University of Medical Sciences, Sabzevar Towhid Town</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Reza Borabadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Sabzevar University of Medical Sciences,  Towhid Town Sabzevar</address>
        <city>Sabzevar</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 51 4464 0115</telephone>
        <email>http://mail.medsab.ac.ir</email>
        <affiliation>Sabzevar University of Medical Sciences, Sabzevar Towhid Town</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Entry criteria Inclination to participate in appropriate blood flow to the affected arteries 18 to 70 years of age Patients underwent trauma under mechanical ventilation up to one week Standard for insufficient bleeding in the blood collection site Lesion or surgical shunt (presence of fistula in it Limb) evidence of peripheral vascular disease in the surrounding area of the cochlear region Coagulopathy or anticoagulant treatment with a moderate to high dose of other patients admitted to other parts of the body Active infection in the arterial pathway and any damage to the limbs include: fracture, dislocation, and Death burn or deterioration of the chest trauma section</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>70 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>T45.9</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Primarily systemic and haematological agent, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Equalize insulin syringes (manufactured by Iran Medical Company) with a 1000-heparin solution (for intervention group) for 1000 heparin units. One heparin injection of 5000 units of the Alborz Drug Company with four cc distilled water in one The 5-cc syringe of the Iran-Tehran Medical Product was diluted and delivered to the 5 th cc, of which every thirty thousand equals 1,000 units), at 0.1 Ml heparinized.</i_keyword>
      <i_keyword>In the control group, based on the status quo, heparin ampoules of 5,000 units were found to be 0.1ml To insert the insulin syringes used for blood sampling, arterial blood gas was used</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Heparin 1000 unit. Timepoint: One day on the first day, the second day, the third day. Method of measurement: Laboratory, arterial blood gas meter.</prim_outcome>
      <prim_outcome>Sodium. Timepoint: One day on the first day, the second day, the third day. Method of measurement: Laboratory, arterial blood gas meter.</prim_outcome>
      <prim_outcome>Kalium. Timepoint: One day on the first day, the second day, the third day. Method of measurement: Laboratory, arterial blood gas meter.</prim_outcome>
      <prim_outcome>Calcium. Timepoint: Onse. Method of measurement: lab Test.</prim_outcome>
      <prim_outcome>Pao2. Timepoint: One day on the first day, the second day, the third day. Method of measurement: Laboratory, arterial blood gas meter.</prim_outcome>
      <prim_outcome>Paco2. Timepoint: Onse. Method of measurement: lab Test.</prim_outcome>
      <prim_outcome>Hco3. Timepoint: Onse. Method of measurement: lab Test.</prim_outcome>
      <prim_outcome>Buffer Base. Timepoint: Onse. Method of measurement: lab Test.</prim_outcome>
      <prim_outcome>Base Exese. Timepoint: One day on the first day, the second day, the third day. Method of measurement: Laboratory, arterial blood gas meter.</prim_outcome>
      <prim_outcome>PH. Timepoint: One day on the first day, the second day, the third day. Method of measurement: Laboratory, arterial blood gas meter.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Heparin 5000 unit. Timepoint: one day, second day,. Method of measurement: Laboratory, arterial blood gas meter.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Sabzevar University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2017-08-13</approval_date>
        <contact_name>Sabzevar University of Medical Sciences</contact_name>
        <contact_address>Sabzevar, Towhid Town Sabzevar  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
